Variation in dengue virus plaque reduction neutralization testing: Systematic review and pooled analysis

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Rainwater Lovett, Kaitlin ^a   Rodriguez Barraquer, Isabel ^a   Cummings, Derek A T ^a   Lessler, Justin ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE;

ARTICLE; CONCENTRATION (PARAMETERS); DENGUE; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; HUMAN; IMMUNOLOGICAL PROCEDURES; NONHUMAN; PLAQUE REDUCTION NEUTRALIZATION TEST; SEROTYPE; STATISTICAL MODEL; STRAIN DIFFERENCE; SYSTEMATIC REVIEW; VACCINATION; VIRUS CHARACTERIZATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE VIRUS; HUMANS; NEUTRALIZATION TESTS; VIRAL PLAQUE ASSAY;

EID: 84870902901     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-233     Document Type: Article

References (49)

1. Deen JL, Harris E, Wills B, Balmaseda A, Hammond SN, Rocha C, et al. The WHO dengue classification and case definitions: time for a reassessment. Lancet 2006, 368:170-173. 10.1016/S0140-6736(06)69006-5, 16829301.
2. Pediatric Dengue Vaccine Initiative: Global Burden of Dengue http://www.pdvi.org/about_dengue/GBD.asp.
3. Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD, Enria DA, et al. Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis 2009, 15:436-440. 10.3201/eid1503.080923, 2681117, 19239758.
4. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967, 99:285-290.
5. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. AmJTrop Med Hyg 2009, 81:825-833.
6. Morens DM, Halstead SB, Larsen LK. Comparison of dengue virus plaque reduction neutralization by macro and "semi-micro' methods in LLC-MK2 cells. Microbiol Immunol 1985, 29:1197-1205.
7. Roehrig JT, Hombach J, Barrett AD. Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses. Viral Immunol 2008, 21:123-132. 10.1089/vim.2008.0007, 18476771.
8. WHO Department of Immunization, Vaccines and Biologicals: Meeting of the WHO Task Force on Clinical Trials of Dengue Vaccines http://whqlibdoc.who.int/hq/2007/WHO_IVB_07.11_eng.pdf.
9. Jin X, Block OT, Rose R, Schlesinger J. Dengue vaccine development and dengue viral neutralization and enhancement assays. Antivir Ther 2009, 14:739-749. 10.3851/IMP1288, 19812436.
10. WHO Dengue: Guidelines for diagnosis, treatment, prevention and control http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf, WHO.
11. WHO Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses http://whqlibdoc.who.int/hq/2007/who_ivb_07.07_eng.pdf, WHO.
12. Durbin AP, Whitehead SS. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 2010, 338:129-143. 10.1007/978-3-642-02215-9_10, 19802583.
13. WHO Regional Office for South-East Asia Comprehensive guidelines for the prevention and control of dengue and dengue hemorrhagic fever http://www.searo.who.int/LinkFiles/Dengue_DHF_prevention&control_guidelines_rev.pdf, WHO Regional Office for South-East Asia.
14. Vazquez S, Cabezas S, Perez AB, Pupo M, Ruiz D, Calzada N, et al. Kinetics of antibodies in sera, saliva, and urine samples from adult patients with primary or secondary dengue 3 virus infections. Int J Infect Dis 2007, 11:256-262. 10.1016/j.ijid.2006.05.005, 16914345.
15. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 1984, 120:653-669.
16. Sturtz S, Ligges U, Gelman A. R2WinBUGS: A package for running WinBUGS from R. J Stat Softw 2005, 12:1-16.
17. Gelman A, Hill J. Multilevel modeling in Bugs and R: the basics. Data Analysis Using Regression and Multilevel/Hierarchical Models 2006, 345-374. Cambridge University Press, New York, 1.
18. Vasilakis N, Durbin AP, da Rosa AP, Munoz-Jordan JL, Tesh RB, Weaver SC. Antigenic relationships between sylvatic and endemic dengue viruses. AmJTrop Med Hyg 2008, 79:128-132.
19. Russell PK, Udomsakdi S, Halstead SB. Antibody response in dengue and dengue hemorrhagic fever. Jpn J Med Sci Biol 1967, 20(Suppl):103-108.
20. Sukhavachana P, Yuill TM, Russell PK. Assay of arbovirus neutralizing antibody by micro methods. Trans R Soc Trop Med Hyg 1969, 63:446-455. 10.1016/0035-9203(69)90031-5, 4309633.
21. Scott RM, McCown JM, Russell PK. Human immunoglobulin specificity after group B arbovirus infections. Infect Immun 1972, 6:277-281. 422528, 4629258.
22. Russell PK, McCown JM. Comparison of dengue-2 and dengue-3 virus strains by neutralization tests and identification of a subtype of dengue-3. AmJTrop Med Hyg 1972, 21:97-99.
23. Halstead SB. Etiologies of the experimental dengues of Siler and Simmons. AmJTrop Med Hyg 1974, 23:974-982.
24. Papaevangelou G, Halstead SB. Infections with two dengue viruses in Greece in the 20th century. Did dengue hemorrhagic fever occur in the 1928 epidemic?. J Trop Med Hyg 1977, 80:46-51.
25. Fujita N, Tamura M, Hotta S. Dengue virus plaque formation on microplate cultures and its application to virus neutralization (38564). Proc Soc Exp Biol Med 1975, 148:472-475.
26. Scott RM, Nimmannitya S, Bancroft WH, Mansuwan P. Shock syndrome in primary dengue infections. AmJTrop Med Hyg 1976, 25:866-874.
27. van Peenen PF, Sunoto, Sumarmo, Sulianti SJ, Sinto S, Joseph PL, et al. Dengue with haemorrhage and shock in Jakarta, Indonesia. Southeast Asian J Trop Med Public Health 1978, 9:25-32.
28. Okuno Y, Fukunaga T, Srisupaluck S, Kasemsarn P, Dharakul C, Sangkawibha N. Serological and virological studies on patients with dengue hemorrhagic fever (DHF) in Chanthaburi province, Thailand. I. Serological studies on paired sera from DHF patients by neutralization (N), hemagglutination inhibition (HI) and staining tests. Biken J 1980, 23:113-121.
29. Fukunaga T, Okuno Y, Tadano M, Fukai K. A retrospective serological study of Japanese who contracted dengue fever in Thailand. Biken J 1983, 26:67-74.
30. Okuno Y, Fukunaga T, Tadano M, Fukai K, Ikeda T, Sekii K, et al. Serological studies on volunteers inoculated experimentally with a dengue virus strain in 1943. Biken J 1983, 26:161-163.
31. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 1985, 22:250-254. 268369, 4031038.
32. Rosen L. Dengue in Greece in 1927 and 1928 and the pathogenesis of dengue hemorrhagic fever: new data and a different conclusion. AmJTrop Med Hyg 1986, 35:642-653.
33. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. AmJTrop Med Hyg 1989, 40:444-451.
34. Kuno G, Gubler DJ, Oliver A. Use of 'original antigenic sin' theory to determine the serotypes of previous dengue infections. Trans R Soc Trop Med Hyg 1993, 87:103-105. 10.1016/0035-9203(93)90444-U, 8465377.
35. Graham RR, Juffrie M, Tan R, Hayes CG, Laksono I, Ma'roef C, et al. A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996. AmJTrop Med Hyg 1999, 61:412-419.
36. Yamada K, Takasaki T, Nawa M, Yabe S, Kurane I. Antibody responses determined for Japanese dengue fever patients by neutralization and hemagglutination inhibition assays demonstrate cross-reactivity between dengue and Japanese encephalitis viruses. Clin Diagn Lab Immunol 2003, 10:725-728. 164242, 12853413.
37. Alvarez M, Rodriguez-Roche R, Bernardo L, Vazquez S, Morier L, Gonzalez D, et al. Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. AmJTrop Med Hyg 2006, 75:1113-1117.
38. Alvarez M, Pavon-Oro A, Rodriguez-Roche R, Bernardo L, Morier L, Sanchez L, et al. Neutralizing antibody response variation against dengue 3 strains. J Med Virol 2008, 80:1783-1789. 10.1002/jmv.21234, 18712848.
39. Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 2008, 82:6631-6643. 10.1128/JVI.00316-08, 2447043, 18448542.
40. da Silva-Nunes M, de Souza VA, Pannuti CS, Speranca MA, Terzian AC, Nogueira ML, et al. Risk factors for dengue virus infection in rural Amazonia: population-based cross-sectional surveys. AmJTrop Med Hyg 2008, 79:485-494.
41. Crill WD, Hughes HR, Delorey MJ, Chang GJ. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 2009, 4:e4991. 10.1371/journal.pone.0004991, 2659788, 19337372.
42. Summers PL, Eckels KH, Dalrymple JM, Scott RM, Boyd VA. Antibody response to dengue-2 vaccine measured by two different radioimmunoassay methods. J Clin Microbiol 1984, 19:651-659. 271149, 6330164.
43. Rabablert J, Dharakul T, Yoksan S, Bhamarapravati N. Dengue virus specific T cell responses to live attenuated monovalent dengue-2 and tetravalent dengue vaccines. Asian Pac J Allergy Immunol 2000, 18:227-235.
44. Rothman AL, Kanesa-Thasan N, West K, Janus J, Saluzzo JF, Ennis FA. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. Vaccine 2001, 19:4694-4699. 10.1016/S0264-410X(01)00236-5, 11535318.
45. Kanesa-Thasan N, Sun W, Ludwig GV, Rossi C, Putnak JR, Mangiafico JA, et al. Atypical antibody responses in dengue vaccine recipients. AmJTrop Med Hyg 2003, 69:32-38.
46. Guy B, Chanthavanich P, Gimenez S, Sirivichayakul C, Sabchareon A, Begue S, et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 2004, 22:3563-3574. 10.1016/j.vaccine.2004.03.042, 15315835.
47. Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006, 24:1238-1241. 10.1016/j.vaccine.2005.09.029, 16213632.
48. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 2009, 5:33-40. 10.4161/hv.5.1.6348, 18670195.
49. Halstead SB. Dengue in the Americas and Southeast Asia: do they differ?. Rev Panam Salud Publica 2006, 20:407-415. 10.1590/S1020-49892006001100007, 17341332.